Free Trial

Viracta Therapeutics (VIRX) Competitors

Viracta Therapeutics logo
$0.01 0.00 (-7.10%)
As of 07/8/2025 03:38 PM Eastern

VIRX vs. QLGN, ONCO, JAGX, VRAX, PTN, AWH, APVO, PCSA, ALZN, and CDT

Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Qualigen Therapeutics (QLGN), Onconetix (ONCO), Jaguar Animal Health (JAGX), Virax Biolabs Group (VRAX), Palatin Technologies (PTN), Aspira Women's Health (AWH), Aptevo Therapeutics (APVO), Heatwurx (PCSA), Alzamend Neuro (ALZN), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical products" industry.

Viracta Therapeutics vs. Its Competitors

Viracta Therapeutics (NASDAQ:VIRX) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Viracta Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500.

Viracta Therapeutics currently has a consensus price target of $1.75, suggesting a potential upside of 12,052.78%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viracta Therapeutics is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viracta Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Qualigen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

31.4% of Viracta Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 10.7% of Viracta Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Viracta Therapeutics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company Overall Sentiment
Viracta Therapeutics Neutral
Qualigen Therapeutics Neutral

Qualigen Therapeutics has higher revenue and earnings than Viracta Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viracta TherapeuticsN/AN/A-$51.06M-$1.10-0.01
Qualigen Therapeutics$4.98M1.13-$6.26MN/AN/A

Qualigen Therapeutics' return on equity of 0.00% beat Viracta Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viracta TherapeuticsN/A -1,899.61% -114.21%
Qualigen Therapeutics N/A N/A N/A

Summary

Viracta Therapeutics beats Qualigen Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Viracta Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VIRX vs. The Competition

MetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$572K$780.02M$5.47B$8.95B
Dividend YieldN/A4.84%5.25%4.06%
P/E Ratio-0.011.0927.0020.10
Price / SalesN/A230.52435.75120.29
Price / CashN/A23.4436.8257.86
Price / Book0.046.137.985.56
Net Income-$51.06M-$27.85M$3.16B$248.40M
7 Day PerformanceN/A0.67%2.40%4.67%
1 Month PerformanceN/A8.48%2.19%6.64%
1 Year PerformanceN/A6.72%33.82%21.31%

Viracta Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VIRX
Viracta Therapeutics
2.1039 of 5 stars
$0.01
-7.1%
$1.75
+12,052.8%
-97.0%$572KN/A-0.0120
QLGN
Qualigen Therapeutics
N/A$3.41
-3.9%
N/A-75.5%$2.61M$4.98M0.0050Gap Up
ONCO
Onconetix
0.288 of 5 stars
$4.77
-1.2%
N/A-99.1%$2.57M$2.52M0.0012Positive News
JAGX
Jaguar Animal Health
2.0844 of 5 stars
$2.52
+0.8%
$60.00
+2,281.0%
-97.4%$2.55M$11.69M0.0050
VRAX
Virax Biolabs Group
2.8416 of 5 stars
$0.79
+1.5%
$3.00
+278.9%
-27.8%$2.52M$160K0.005Positive News
PTN
Palatin Technologies
N/A$0.09
-44.6%
N/AN/A$2.45M$350K-0.0630Gap Down
High Trading Volume
AWH
Aspira Women's Health
0.9028 of 5 stars
$0.08
-12.5%
$5.50
+6,607.3%
-93.4%$2.44M$9.18M-0.07110High Trading Volume
APVO
Aptevo Therapeutics
2.0968 of 5 stars
$3.05
-1.0%
$219,040.00
+7,181,539.3%
-100.0%$2.33M$3.11M0.0050
PCSA
Heatwurx
3.7698 of 5 stars
$0.21
+4.5%
$2.00
+875.6%
-86.8%$2.33MN/A-0.0720
ALZN
Alzamend Neuro
2.2331 of 5 stars
$2.91
+0.3%
$180.00
+6,085.6%
-92.9%$2.32MN/A0.004News Coverage
Positive News
CDT
Conduit Pharmaceuticals
N/A$2.76
-4.2%
N/A-99.7%$2.30MN/A-0.013News Coverage
High Trading Volume

Related Companies and Tools


This page (NASDAQ:VIRX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners